; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255558" data-permalink="https://rxharun.com/rxharun/drug-a-z/glasdegib/attachment/glasdegib-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Glasdegib – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/glasdegib/" data-jpibfi-post-title="Glasdegib – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/glasdegib-uses-dosage-side-effects-interaction_245749.jpg?fit=800%2C600&ssl=1">
Glasdegib is an orally available small molecule inhibitor of the signaling molecule hedgehog which is used as an antineoplastic agent in the treatment of acute myeloid leukemia. Glasdegib is associated with a moderate rate of serum aminotransferase elevations during therapy and is suspected to cause rare instances of clinically apparent acute liver injury.
Glasdegib is a member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a (2R,4S)-4-{[(4-cyanophenyl)carbamoyl]amino}-1-methylpiperidin-2-yl group at position 2. It is a hedgehog signaling pathway inhibitor that acts by binding to Smoothened (SMO) receptors and blocking signal transduction (IC50 = 5 nM). It is used in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients (aged >= 75 years), or who have medical conditions that prevent the use of standard chemotherapy. It has a role as an SMO receptor antagonist, a Hedgehog signaling pathway inhibitor, and an antineoplastic agent. It is a member of benzimidazoles, a member of piperidines, a member of phenyl ureas, and a nitrile.
Glasdegib is an orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling. The Hh signaling pathway plays an important role in cellular growth, differentiation, and repair. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies.
Glasdegib Maleate is the maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets bind to and inhibit the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers.
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed.[rx]Glasdegib was developed by Pfizer Inc and approved on November 21, 2018, by the FDA for the treatment of Acute Myeloid Leukemia.[rx]
Mechanism of Action
Glasdegib is a potent and selective inhibitor of the hedgehog signaling pathway that acts by binding to the smoothened (SMO) receptor. The hedgehog signaling pathway is involved in the maintenance of neural and skin stem cells. In this pathway, the binding of specific ligands to the transmembrane receptor patched (PTCH1) allows the activation of the transcriptional regulators GL11, GL12, and modulation of the gene expression through SMO-mediated signaling. The aberrant activation of the hedgehog pathway is thought to be implicated in the pathogenesis of chronic myeloid leukemia, medulloblastoma, and basal cell carcinoma due to the hyperproliferative state that a modification of this pathway will produce.
In preclinical studies, glasdegib achieved a significant reduction in leukemic stem cell burden in xenograft models and a reduction in the cell population expressing leukemic stem cell markers. In clinical trials, glasdegib demonstrated a marked downregulation of more than 80% of the expression of glioma-associated transcriptional regulator GL11 in the skin. In this same study, 8% of the studied individuals with acute myeloid leukemia achieved morphological complete remission while 31% achieved a stable disease state. The latest clinical trial proved glasdegib to generate an overall survival of 8.3 months which was almost double what has been observed in patients under low-dose cytarabine treatment. As well, there have been reports of dose-dependent QTc prolongation in patients administered with glasdegib.
Indications
- Glasdegib, in combination with cytarabine, is indicated for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are over 75 years old or that have co-morbidities that preclude intensive induction chemotherapy. Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of the blood and bone marrow and it is the most common type of acute leukemia in adults.
- Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
- Glasdegib is an orally available small molecule inhibitor of the signaling molecule hedgehog which is used as an antineoplastic agent in the treatment of acute myeloid leukemia.
- Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
- Glasdegib is a sonic hedgehog receptor inhibitor used to treat newly diagnosed acute myeloid leukemia in patients over 75 years who cannot receive intense chemotherapy.
- This drug, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older or who have comorbidities that preclude use of intensive induction chemotherapy.
Acute myeloid leukemia is characterized by abnormal production of myeloblasts, red cells, or platelets. It is considered a cancer of blood and bone marrow and it is the most common type of acute leukemia in adults.
Use in Cancer
Glasdegib maleate is approved to treat:
- Acute myeloid leukemia that is newly diagnosed. It is used with low-dose cytarabine in patients aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy.
Glasdegib maleate is also being studied in the treatment of other types of cancer.
Contraindications
- are allergic to glasdegib or any ingredients of the medication
- are male and are unwilling or unable to use effective birth control
- are female, may become pregnant, and are unwilling or unable to use effective birth control
- are pregnant
- are breast-feeding
- low amount of magnesium in the blood
- low amount of potassium in the blood
- prolonged QT interval on EKG
- chronic heart failure
- abnormal EKG with QT changes from birth
- pregnancy
- a patient who is producing milk and breastfeeding
Dosage
Strengths: 25 mg; 100 mg
Acute Myeloid Leukemia
- 100 mg orally once a day on days 1 to 28 in combination with cytarabine 20 mg subcutaneously 2 times a day on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control; for patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response=
Acute Myeloid Leukemia
75 years or older:
- 100 mg orally once a day on days 1 to 28 in combination with cytarabine 20 mg subcutaneously 2 times a day on days 1 to 10 of each 28-day cycle in the absence of unacceptable toxicity or loss of disease control; for patients without unacceptable toxicity, treat for a minimum of 6 cycles to allow time for clinical response
Dose Adjustments
Dose Modifications for Adverse Reactions:
QTC INTERVAL PROLONGATION ON AT LEAST 2 SEPARATE ELECTROCARDIOGRAMS (ECGS):
- QTc interval greater than 480 ms to 500 ms: Assess electrolyte levels as clinically indicated; review and adjust concomitant medications with known QTc interval-prolonging effects; monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation to less than or equal to 480 ms.
- QTc interval greater than 500 ms: Assess electrolyte levels and supplement as clinically indicated; review and adjust concomitant medications with known QTc interval-prolonging effects; interrupt therapy; resume therapy at a reduced dose of 50 mg once daily when QTc interval returns to within 30 ms of baseline or less than or equal to 480 ms; monitor ECGs at least weekly for 2 weeks following resolution of QTc prolongation; consider re-escalating the dose to 100 mg daily if an alternative etiology for the QTc prolongation can be identified.
- QTc interval prolongation with life-threatening arrhythmia: Permanently discontinue therapy.
HEMATOLOGIC TOXICITY:
- Platelets less than 10 GI/L for more than 42 days in the absence of disease: Discontinue this drug and low-dose cytarabine permanently.
- Neutrophil count less than 0.5 GI/L for more than 42 days in the absence of disease: Discontinue this drug and low-dose cytarabine permanently.
NONHEMATOLOGIC TOXICITY:
- Grade 3: Interrupt this drug and/or low-dose cytarabine until symptoms reduce to mild or return to baseline; resume this drug at the same dose level, or at a reduced dose of 50 mg; resume low-dose cytarabine at the same dose level, or at a reduced dose of 10 or 15 mg; if toxicity recurs, discontinue this drug and low-dose cytarabine; if toxicity is attributable to this drug only, low-dose cytarabine may be continued.
- Grade 4: Discontinue this drug and low-dose cytarabine permanently.
DOSE MODIFICATION FOR CONCOMITANT USE WITH MODERATE CYP450 3A4 INDUCERS:
- Avoid concomitant use of this drug with moderate CYP450 3A4 inducers.
- If concomitant use cannot be avoided, increase the dose of this drug as tolerated as shown below:
- After the moderate CYP450 3A4 inducer has been discontinued for 7 days, resume this drug at the dose taken prior to initiating the moderate CYP450 3A4 inducer.
DOSE MODIFICATION OF THIS DRUG WHEN TAKEN WITH MODERATE CYP450 INDUCERS:
- If the current dose is 100 mg once a day: Increase it to 200 mg orally once a day.
- If the current dose is 50 mg orally once a day: Increase it to 100 mg orally once a day.
Administration advice:
- This drug may be taken with or without food.
- Do not split, divide, or crush tablets.
- Administer at the same time each day.
- If a dose is vomited, do not administer a replacement dose; wait until the next scheduled dose is due.
- If a dose is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day.
- Do not administer 2 doses within 12 hours.
Monitoring:
- Assess complete blood counts, electrolytes, renal, and hepatic function prior to the initiation of therapy and at least once a week for the first month.
- Monitor electrolytes and renal function once monthly for the duration of therapy.
- Obtain serum creatine kinase levels prior to initiating therapy and as indicated clinically thereafter (e.g., if muscle symptoms are reported).
- Monitor electrocardiograms (ECGs) prior to the initiation of therapy, approximately 1 week after initiation, and then once monthly for the next 2 months to assess for QTc prolongation. Repeat ECG if abnormal. Some patients may require more frequent and ongoing ECG monitoring.
Side Effects
The Most Common
- muscle spasms
- muscle, bone or joint pain
- extreme tiredness
- nausea
- vomiting
- abdominal pain
- constipation
- pain or sores in your mouth or throat
- decreased appetite
- change in the way things taste
- weight loss
- headache
- rash
- swelling of hands or legs
- hair loss
- toothache
- feeling faint, lightheaded, or dizzy; fast or irregular heartbeat
- unusual bruising or bleeding
- fever alone or along with chills, and weakness. or other signs of infection
- decreased urination
- chest pain
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- chest pain
- chills
- confusion
- cough
- coughing up blood
- decreased frequency or amount of urine
- difficult or labored breathing
- difficulty in swallowing
- dizziness or fainting
- drowsiness
- dry mouth
- fainting
- fast, slow, or irregular heartbeat
- fever
- headache
- increased blood pressure
- increased menstrual flow or vaginal bleeding
- increased thirst
- lightheadedness
- loss of appetite
- loss of consciousness
- lower back or side pain
- mood or mental changes
- muscle pain or cramps
- muscle spasms (tetany) or twitching seizures
- nausea
- nervousness
- nosebleeds
- numbness or tingling in the hands, feet, or lips
- painful or difficult urination
- pale skin
- paralysis
- pinpoint red spots on the skin
- pounding heartbeat
- prolonged bleeding from cuts
- rapid, shallow breathing
- red or black, tarry stools
- red or dark brown urine
- seizures
- sneezing
- sore throat
- stomach pain
- swelling of the face, hands, ankles, or lower legs
- tightness in the chest
- trembling
- troubled breathing with exertion
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting
- weakness or heaviness of the legs
- weight gain
- Bone or muscle pain
- change in taste
- constipation
- cracked lips
- decreased appetite
- diarrhea
- loose tooth
- loss of taste
- skin rash
- thinning or loss of hair
- toothache
Rare
- changes in sense of taste
- decreased appetite
- fatigue
- hair loss
- headache
- muscle, joint, or bone pain
- muscle spasms or tightness
- nausea
- rash
- sores or pain in the mouth or throat
- stomach pain
- toothache or lose tooth
- weakness
- weight loss
- irregular heartbeat (e.g., fast, slow, or pounding heartbeat; shortness of breath; dizziness)
- signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
- signs of clotting problems (e.g., unusual nosebleeds, bruising, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
- signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
- signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain)
- swelling arms, legs, face
- symptoms of low sodium levels in the blood (e.g., achy, stiff, or uncoordinated muscles; confusion; tiredness; weakness)
- symptoms of pneumonia (e.g., fever or chills, shortness of breath, fatigue, chest pain, cough)
- eye bleeding (e.g., blurred vision, pain when exposed to light, eye bruising)
- severe breathing problems (respiratory failure: blue color to skin, lips, or fingernails; sleepiness; irregular heartbeat; shortness of breath; loss of consciousness)
- signs of bleeding in the stomach (e.g., bloody, black, or tarry stools; spitting up blood; vomiting blood or material that looks like coffee grounds)
- signs of bleeding in the brain (e.g., sudden or severe headache; sudden loss of coordination; vision changes; sudden slurring of speech; or unexplained weakness, numbness, or pain in arm or leg)
- signs of a heart attack (e.g., sudden chest pain or pain radiating to back, down arm, jaw; sensation of fullness of the chest; nausea; vomiting; sweating; anxiety)
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abametapir | The serum concentration of Glasdegib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Glasdegib can be increased when combined with Abatacept. |
| Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Glasdegib. |
| Abiraterone | The metabolism of Glasdegib can be decreased when combined with Abiraterone. |
| Abrocitinib | The serum concentration of Glasdegib can be increased when it is combined with Abrocitinib. |
| Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Glasdegib. |
| Acyclovir | The excretion of Acyclovir can be decreased when combined with Glasdegib. |
| Adalimumab | The metabolism of Glasdegib can be increased when combined with Adalimumab. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Glasdegib. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Glasdegib. |
| Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Glasdegib. |
| Alectinib | Alectinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Glasdegib. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Glasdegib. |
| Allopurinol | Glasdegib may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
| Almotriptan | The metabolism of Glasdegib can be decreased when combined with Almotriptan. |
| Alpelisib | The serum concentration of Alpelisib can be increased when it is combined with Glasdegib. |
| Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Glasdegib. |
| Ambrisentan | The serum concentration of Ambrisentan can be increased when it is combined with Glasdegib. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Glasdegib. |
| Aminophenazone | The metabolism of Glasdegib can be decreased when combined with Aminophenazone. |
| Amiodarone | The metabolism of Glasdegib can be decreased when combined with Amiodarone. |
| Amisulpride | The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Glasdegib. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Glasdegib. |
| Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Glasdegib. |
| Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Glasdegib. |
| Amprenavir | The metabolism of Glasdegib can be decreased when combined with Amprenavir. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Glasdegib. |
| Anakinra | The metabolism of Glasdegib can be increased when combined with Anakinra. |
| Anastrozole | The metabolism of Glasdegib can be decreased when combined with Anastrozole. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Antazoline is combined with Glasdegib. |
| Antipyrine | The metabolism of Glasdegib can be decreased when combined with Antipyrine. |
| Apalutamide | The serum concentration of Glasdegib can be decreased when it is combined with Apalutamide. |
| Apixaban | Glasdegib may decrease the excretion rate of Apixaban which could result in a higher serum level. |
| Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Glasdegib. |
| Apremilast | The metabolism of Glasdegib can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Glasdegib can be decreased when combined with Aprepitant. |
| Arformoterol | The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Glasdegib. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Glasdegib. |
| Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Glasdegib. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Glasdegib. |
| Artemether | The risk or severity of QTc prolongation can be increased when Artemether is combined with Glasdegib. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Articaine. |
| Asciminib | The serum concentration of Glasdegib can be increased when it is combined with Asciminib. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Asenapine is combined with Glasdegib. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Astemizole is combined with Glasdegib. |
| Asunaprevir | The serum concentration of Glasdegib can be increased when it is combined with Asunaprevir. |
| Atazanavir | The metabolism of Glasdegib can be decreased when combined with Atazanavir. |
| Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Glasdegib. |
| Atorvastatin | The metabolism of Glasdegib can be decreased when combined with Atorvastatin. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Glasdegib. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Glasdegib. |
| Avatrombopag | Avatrombopag may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Glasdegib. |
| Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Glasdegib. |
| Azelastine | The metabolism of Glasdegib can be decreased when combined with Azelastine. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Glasdegib. |
| Baricitinib | The excretion of Baricitinib can be decreased when combined with Glasdegib. |
| Beclomethasone | Beclomethasone dipropionate may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Glasdegib. |
| Belantamab | The serum concentration of Belantamab mafodotin can be increased when it is combined with Glasdegib. |
| Belinostat | The serum concentration of Belinostat can be increased when it is combined with Glasdegib. |
| Belumosudil | Belumosudil may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Glasdegib. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Glasdegib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Benzyl alcohol. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Bepridil is combined with Glasdegib. |
| Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Glasdegib. |
| Betamethasone | The metabolism of Glasdegib can be increased when combined with Betamethasone. |
| Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Glasdegib. |
| Bexarotene | The metabolism of Glasdegib can be decreased when combined with Bexarotene. |
| Bezafibrate | The metabolism of Glasdegib can be decreased when combined with Bezafibrate. |
| Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Glasdegib. |
| Bimekizumab | The metabolism of Glasdegib can be increased when combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Glasdegib. |
| Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Glasdegib. |
| Boceprevir | The metabolism of Glasdegib can be decreased when combined with Boceprevir. |
| Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Glasdegib. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Glasdegib. |
| Brentuximab | The serum concentration of Brentuximab vedotin can be increased when it is combined with Glasdegib. |
| Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Glasdegib. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Glasdegib. |
| Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Glasdegib. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Glasdegib. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Bupivacaine. |
| Buprenorphine | Buprenorphine may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Glasdegib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Butamben. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Glasdegib. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Glasdegib. |
| Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Glasdegib. |
| Cabozantinib | The metabolism of Glasdegib can be decreased when combined with Cabozantinib. |
| Caffeine | Caffeine may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Canagliflozin | The serum concentration of Glasdegib can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Glasdegib can be increased when combined with Canakinumab. |
| Candesartan | The metabolism of Glasdegib can be decreased when combined with Candesartan cilexetil. |
| Cannabidiol | Cannabidiol may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Capmatinib | The serum concentration of Glasdegib can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Capsaicin. |
| Carbamazepine | The metabolism of Glasdegib can be increased when combined with Carbamazepine. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Glasdegib. |
| Carfilzomib | The serum concentration of Carfilzomib can be increased when it is combined with Glasdegib. |
| Carvedilol | The serum concentration of Glasdegib can be increased when it is combined with Carvedilol. |
| Cefradine | The excretion of Cefradine can be decreased when combined with Glasdegib. |
| Celecoxib | Glasdegib may decrease the excretion rate of Celecoxib which could result in a higher serum level. |
| Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Glasdegib. |
| Cenobamate | The serum concentration of Glasdegib can be decreased when it is combined with Cenobamate. |
| Cephalexin | The excretion of Cephalexin can be decreased when combined with Glasdegib. |
| Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Glasdegib. |
| Cerivastatin | Glasdegib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. |
| Certolizumab | The metabolism of Glasdegib can be increased when combined with Certolizumab pegol. |
| Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Glasdegib. |
| Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Glasdegib. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Chloroprocaine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Glasdegib. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Glasdegib. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Glasdegib. |
| Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Glasdegib. |
| Cholesterol | Cholesterol may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy. |
| Cilostazol | The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Glasdegib. |
| Cimetidine | The metabolism of Glasdegib can be decreased when combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Cinchocaine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Glasdegib. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Glasdegib. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Glasdegib. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Cisapride is combined with Glasdegib. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Citalopram is combined with Glasdegib. |
| Cladribine | Glasdegib may decrease the excretion rate of Cladribine which could result in a higher serum level. |
| Clarithromycin | The metabolism of Glasdegib can be decreased when combined with Clarithromycin. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Clemastine is combined with Glasdegib. |
| Clobazam | The serum concentration of Clobazam can be increased when it is combined with Glasdegib. |
| Clofarabine | Glasdegib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Clofazimine | The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Glasdegib. |
| Clomifene | The serum concentration of Clomifene can be increased when it is combined with Glasdegib. |
| Clomipramine | The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Glasdegib. |
| Clopidogrel | The metabolism of Glasdegib can be decreased when combined with Clopidogrel. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Clozapine is combined with Glasdegib. |
| Cobicistat | The metabolism of Glasdegib can be decreased when combined with Cobicistat. |
| Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Glasdegib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Cocaine. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Glasdegib. |
| Conivaptan | The metabolism of Glasdegib can be decreased when combined with Conivaptan. |
| Conjugated | Glasdegib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
| Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Glasdegib. |
| Crizotinib | The serum concentration of Crizotinib can be increased when it is combined with Glasdegib. |
| Curcumin | The metabolism of Glasdegib can be decreased when combined with Curcumin. |
| Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Glasdegib. |
| Cyclophosphamide | The metabolism of Glasdegib can be increased when combined with Cyclophosphamide. |
| Cyclosporine | The serum concentration of Cyclosporine can be increased when it is combined with Glasdegib. |
| Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Glasdegib. |
| Dabigatran | The serum concentration of Dabigatran etexilate can be increased when it is combined with Glasdegib. |
| Dabrafenib | The serum concentration of Glasdegib can be decreased when it is combined with Dabrafenib. |
| Daclatasvir | Daclatasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with Glasdegib. |
| Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Glasdegib. |
| Danazol | The metabolism of Glasdegib can be decreased when combined with Danazol. |
| Dapsone | The metabolism of Glasdegib can be decreased when combined with Dapsone. |
| Daptomycin | The serum concentration of Daptomycin can be increased when it is combined with Glasdegib. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Glasdegib. |
| Darolutamide | The serum concentration of Glasdegib can be increased when it is combined with Darolutamide. |
| Darunavir | The metabolism of Glasdegib can be decreased when combined with Darunavir. |
| Dasabuvir | Dasabuvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Glasdegib. |
| Daunorubicin | Glasdegib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. |
| Deferasirox | The metabolism of Glasdegib can be decreased when combined with Deferasirox. |
| Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Glasdegib. |
| Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Glasdegib. |
| Delamanid | Glasdegib may increase the QTc-prolonging activities of Delamanid. |
| Delavirdine | The metabolism of Glasdegib can be decreased when combined with Delavirdine. |
| Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Glasdegib. |
| Desipramine | The risk or severity of QTc prolongation can be increased when Desipramine is combined with Glasdegib. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Glasdegib. |
| Desvenlafaxine | The metabolism of Glasdegib can be decreased when combined with Desvenlafaxine. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Deutetrabenazine. |
| Dexamethasone | The metabolism of Glasdegib can be increased when combined with Dexamethasone. |
| Dexamethasone | Dexamethasone acetate may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Dexbromphenir | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Glasdegib. |
| Dexchlorphenir | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Glasdegib. |
| Dexibuprofen | The metabolism of Glasdegib can be decreased when combined with Dexibuprofen. |
| Diclofenac | The metabolism of Glasdegib can be decreased when combined with Diclofenac. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Diflunisal | The metabolism of Glasdegib can be decreased when combined with Diflunisal. |
| Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Glasdegib. |
| Digoxin | Glasdegib may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Glasdegib. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Glasdegib. |
| Diosmin | The serum concentration of Glasdegib can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Diphenhydramine. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Glasdegib. |
| Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Glasdegib. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Glasdegib. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Glasdegib. |
| Dolutegravir | Glasdegib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Domperidone is combined with Glasdegib. |
| Donepezil | Glasdegib may decrease the excretion rate of Donepezil which could result in a higher serum level. |
| Dosulepin | The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Glasdegib. |
| Doxepin | The risk or severity of QTc prolongation can be increased when Doxepin is combined with Glasdegib. |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Glasdegib. |
| Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Glasdegib. |
| Dronedarone | Glasdegib may increase the QTc-prolonging activities of Dronedarone. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Glasdegib. |
| Duvelisib | Glasdegib may decrease the excretion rate of Duvelisib which could result in a higher serum level. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Dyclonine. |
| Ebastine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Glasdegib. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Glasdegib. |
| Efavirenz | The metabolism of Glasdegib can be decreased when combined with Efavirenz. |
| Elagolix | The serum concentration of Elagolix can be increased when it is combined with Glasdegib. |
| Elbasvir | Elbasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Eliglustat | The serum concentration of Glasdegib can be increased when it is combined with Eliglustat. |
| Eltrombopag | The metabolism of Glasdegib can be decreased when combined with Eltrombopag. |
| Elvitegravir | The metabolism of Glasdegib can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Glasdegib can be increased when combined with Emapalumab. |
| Emedastine | The risk or severity of QTc prolongation can be increased when Emedastine is combined with Glasdegib. |
| Emtricitabine | The excretion of Emtricitabine can be decreased when combined with Glasdegib. |
| Enasidenib | The metabolism of Enasidenib can be decreased when combined with Glasdegib. |
| Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Glasdegib. |
| Encorafenib | The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Glasdegib. |
| Enfortumab vedotin | The serum concentration of Enfortumab vedotin can be increased when it is combined with Glasdegib. |
| Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Glasdegib. |
| Entrectinib | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Entrectinib. |
| Enzalutamide | The serum concentration of Glasdegib can be decreased when it is combined with Enzalutamide. |
| Epinastine | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Glasdegib. |
| Erdafitinib | The serum concentration of Glasdegib can be increased when it is combined with Erdafitinib. |
| Ergotamine | The metabolism of Glasdegib can be decreased when combined with Ergotamine. |
| Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Glasdegib. |
| Erlotinib | The metabolism of Erlotinib can be decreased when combined with Glasdegib. |
| Ertugliflozin | Glasdegib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Glasdegib. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Glasdegib. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Glasdegib. |
| Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Glasdegib. |
| Estradiol | Estradiol may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Estradiol acetate | Estradiol acetate may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Estradiol benzoate | Estradiol benzoate may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Estradiol cypionate | Estradiol cypionate may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Estradiol dienanthate | Estradiol dienanthate may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Estradiol valerate | Estradiol valerate may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Estrone sulfate | The excretion of Estrone sulfate can be decreased when combined with Glasdegib. |
| Eszopiclone | The metabolism of Glasdegib can be decreased when combined with Eszopiclone. |
| Etanercept | The metabolism of Glasdegib can be increased when combined with Etanercept. |
| Ethinylestradiol | The metabolism of Glasdegib can be decreased when combined with Ethinylestradiol. |
| Ethosuximide | The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Glasdegib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Etidocaine. |
| Etoposide | The serum concentration of Etoposide can be increased when it is combined with Glasdegib. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Glasdegib. |
| Ezetimibe | Glasdegib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. |
| Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Glasdegib. |
| Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Glasdegib. |
| Favipiravir | The serum concentration of Glasdegib can be increased when it is combined with Favipiravir. |
| Febuxostat | The excretion of Glasdegib can be decreased when combined with Febuxostat. |
| Fedratinib | Fedratinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Felbamate | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Glasdegib. |
| Felodipine | The metabolism of Glasdegib can be decreased when combined with Felodipine. |
| Fenofibrate | The metabolism of Glasdegib can be decreased when combined with Fenofibrate. |
| Fexinidazole | The risk or severity of adverse effects can be increased when Glasdegib is combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Fexofenadine can be increased when it is combined with Glasdegib. |
| Finerenone | The metabolism of Finerenone can be decreased when combined with Glasdegib. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Flecainide is combined with Glasdegib. |
| Flibanserin | The serum concentration of Glasdegib can be increased when it is combined with Flibanserin. |
| Fluconazole | The metabolism of Glasdegib can be decreased when combined with Fluconazole. |
| Fluorouracil | The metabolism of Fluorouracil can be decreased when combined with Glasdegib. |
| Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Glasdegib. |
| Flupentixol | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Flupentixol. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Glasdegib. |
| Fluticasone | The metabolism of Glasdegib can be decreased when combined with Fluticasone. |
| Fluticasone furoate | The metabolism of Glasdegib can be decreased when combined with Fluticasone furoate. |
| Fluticasone | The metabolism of Glasdegib can be decreased when combined with Fluticasone propionate. |
| Fluvastatin | The metabolism of Glasdegib can be decreased when combined with Fluvastatin. |
| Fluvoxamine | The metabolism of Glasdegib can be decreased when combined with Fluvoxamine. |
| Folic acid | Glasdegib may decrease the excretion rate of Folic acid which could result in a higher serum level. |
| Formoterol | The risk or severity of QTc prolongation can be increased when Formoterol is combined with Glasdegib. |
| Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Glasdegib. |
| Fosnetupitant | The metabolism of Glasdegib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Fosphenytoin can be decreased when combined with Glasdegib. |
| Fostamatinib | Fostamatinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Fostemsavir | The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Glasdegib. |
| Fusidic acid | The metabolism of Glasdegib can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Glasdegib. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Glasdegib. |
| Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Glasdegib. |
| Ganciclovir | The excretion of Ganciclovir can be decreased when combined with Glasdegib. |
| Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Glasdegib. |
| Gefitinib | Gefitinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Glasdegib. |
| Gemfibrozil | The metabolism of Glasdegib can be decreased when combined with Gemfibrozil. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Glasdegib. |
| Gilteritinib | The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Glasdegib. |
| Glecaprevir | Glasdegib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. |
| Glyburide | Glasdegib may decrease the excretion rate of Glyburide which could result in a higher serum level. |
| Golimumab | The metabolism of Glasdegib can be increased when combined with Golimumab. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Glasdegib. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Glasdegib. |
| Grazoprevir | Grazoprevir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Glasdegib. |
| Guanidine | The excretion of Guanidine can be decreased when combined with Glasdegib. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Glasdegib. |
| Haloperidol | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Haloperidol. |
| Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Glasdegib. |
| Hydrochlorothiazide | The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Glasdegib. |
| Hydrocortisone | The metabolism of Glasdegib can be increased when combined with Hydrocortisone. |
| Hydroxychloroquine | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Glasdegib. |
| Hydroxyzine | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Hydroxyzine. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Glasdegib. |
| Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Glasdegib. |
| Ibuprofen | The metabolism of Glasdegib can be decreased when combined with Ibuprofen. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Glasdegib. |
| Idelalisib | Glasdegib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
| Ifosfamide | The metabolism of Glasdegib can be increased when combined with Ifosfamide. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Iloperidone is combined with Glasdegib. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Imatinib is combined with Glasdegib. |
| Imipramine | The serum concentration of Imipramine can be increased when it is combined with Glasdegib. |
| Indacaterol | The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Glasdegib. |
| Indapamide | The risk or severity of QTc prolongation can be increased when Indapamide is combined with Glasdegib. |
| Indinavir | The metabolism of Glasdegib can be decreased when combined with Indinavir. |
| Infliximab | The metabolism of Glasdegib can be increased when combined with Infliximab. |
| Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Glasdegib. |
| Inotuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glasdegib. |
| Irbesartan | The metabolism of Glasdegib can be decreased when combined with Irbesartan. |
| Irinotecan | Glasdegib may decrease the excretion rate of Irinotecan which could result in a higher serum level. |
| Isavuconazole | The serum concentration of Glasdegib can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Glasdegib can be increased when it is combined with Isavuconazonium. |
| Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Glasdegib. |
| Isoniazid | The metabolism of Glasdegib can be decreased when combined with Isoniazid. |
| Isradipine | The metabolism of Glasdegib can be decreased when combined with Isradipine. |
| Istradefylline | Istradefylline may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Itraconazole | The metabolism of Glasdegib can be decreased when combined with Itraconazole. |
| Ivabradine | The risk or severity of QTc prolongation can be increased when Ivabradine is combined with Glasdegib. |
| Ivacaftor | The serum concentration of Glasdegib can be increased when it is combined with Ivacaftor. |
| Ivermectin | Glasdegib may decrease the excretion rate of Ivermectin which could result in a higher serum level. |
| Ivosidenib | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ivosidenib. |
| Ixabepilone | The serum concentration of Glasdegib can be increased when it is combined with Ixabepilone. |
| Ketamine | The metabolism of Glasdegib can be decreased when combined with Ketamine. |
| Ketoconazole | The metabolism of Glasdegib can be decreased when combined with Ketoconazole. |
| Ketoprofen | The metabolism of Glasdegib can be decreased when combined with Ketoprofen. |
| Ketorolac | The metabolism of Glasdegib can be decreased when combined with Ketorolac. |
| Lacidipine | The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Glasdegib. |
| Lamivudine | Glasdegib may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
| Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Glasdegib. |
| Lansoprazole | Lansoprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Lapatinib | The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Glasdegib. |
| Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Glasdegib. |
| Lasmiditan | The serum concentration of Glasdegib can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Glasdegib. |
| Lefamulin | Lefamulin may increase the QTc-prolonging activities of Glasdegib. |
| Leflunomide | Glasdegib may decrease the excretion rate of Leflunomide which could result in a higher serum level. |
| Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Glasdegib. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Glasdegib. |
| Letermovir | Letermovir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Glasdegib. |
| Levacetylmethadol | The risk or severity of QTc prolongation can be increased when Levacetylmethadol is combined with Glasdegib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Levobupivacaine. |
| Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Glasdegib. |
| Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Glasdegib. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Glasdegib. |
| Levoketoconazole | The metabolism of Glasdegib can be decreased when combined with Levoketoconazole. |
| Levomenthol | The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Glasdegib. |
| Levomilnacipran | The metabolism of Glasdegib can be decreased when combined with Levomilnacipran. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Glasdegib. |
| Levothyroxine | The metabolism of Glasdegib can be decreased when combined with Levothyroxine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Lidocaine. |
| Lidoflazine | The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Glasdegib. |
| Linagliptin | The metabolism of Glasdegib can be decreased when combined with Linagliptin. |
| Linzagolix | The serum concentration of Glasdegib can be increased when it is combined with Linzagolix. |
| Liotrix | The metabolism of Glasdegib can be decreased when combined with Liotrix. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Glasdegib. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Glasdegib. |
| Lomitapide | The serum concentration of Glasdegib can be increased when it is combined with Lomitapide. |
| Lonafarnib | The metabolism of Glasdegib can be decreased when combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Glasdegib. |
| Loperamide | The excretion of Loperamide can be decreased when combined with Glasdegib. |
| Lopinavir | The metabolism of Glasdegib can be decreased when combined with Lopinavir. |
| Loratadine | The metabolism of Glasdegib can be decreased when combined with Loratadine. |
| Losartan | The risk or severity of QTc prolongation can be increased when Losartan is combined with Glasdegib. |
| Lovastatin | The metabolism of Glasdegib can be decreased when combined with Lovastatin. |
| Loxapine | The serum concentration of Glasdegib can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Glasdegib can be decreased when it is combined with Lumacaftor. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Glasdegib. |
| Lurasidone | The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Glasdegib. |
| Lusutrombopag | Glasdegib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Macimorelin. |
| Mannitol | The serum concentration of Mannitol can be increased when it is combined with Glasdegib. |
| Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Glasdegib. |
| Maribavir | Maribavir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Mavacamten | The serum concentration of Glasdegib can be decreased when it is combined with Mavacamten. |
| Medroxyprogeste | The metabolism of Glasdegib can be decreased when combined with Medroxyprogesterone acetate. |
| Mefenamic acid | The metabolism of Glasdegib can be decreased when combined with Mefenamic acid. |
| Mefloquine | The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Glasdegib. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Meloxicam. |
| Mephenytoin | The metabolism of Glasdegib can be decreased when combined with Mephenytoin. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Mepivacaine. |
| Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Glasdegib. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Glasdegib. |
| Mestranol | The metabolism of Glasdegib can be decreased when combined with Mestranol. |
| Metformin | The excretion of Metformin can be decreased when combined with Glasdegib. |
| Methadone | The risk or severity of QTc prolongation can be increased when Methadone is combined with Glasdegib. |
| Methimazole | The metabolism of Glasdegib can be decreased when combined with Methimazole. |
| Methotrexate | Glasdegib may decrease the excretion rate of Methotrexate which could result in a higher serum level. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Glasdegib. |
| Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Glasdegib. |
| Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Glasdegib. |
| Methylene blue | The serum concentration of Glasdegib can be increased when it is combined with Methylene blue. |
| Metoclopramide | The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Glasdegib. |
| Metreleptin | The metabolism of Glasdegib can be increased when combined with Metreleptin. |
| Metronidazole | The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Glasdegib. |
| Miconazole | The metabolism of Glasdegib can be decreased when combined with Miconazole. |
| Midostaurin | The metabolism of Glasdegib can be decreased when combined with Midostaurin. |
| Mifepristone | The serum concentration of Glasdegib can be increased when it is combined with Mifepristone. |
| Milnacipran | The metabolism of Glasdegib can be decreased when combined with Milnacipran. |
| Mirabegron | The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Glasdegib. |
| Mirtazapine | The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Glasdegib. |
| Mitapivat | The serum concentration of Glasdegib can be increased when it is combined with Mitapivat. |
| Mitotane | The metabolism of Glasdegib can be increased when combined with Mitotane. |
| Mitoxantrone | Glasdegib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Glasdegib. |
| Mobocertinib | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Mobocertinib. |
| Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Glasdegib. |
| Mometasone | The metabolism of Glasdegib can be decreased when combined with Mometasone furoate. |
| Montelukast | The metabolism of Glasdegib can be decreased when combined with Montelukast. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Glasdegib. |
| Morphine | The serum concentration of Morphine can be increased when it is combined with Glasdegib. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Glasdegib. |
| Mycophenolate | Glasdegib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. |
| Nadolol | The excretion of Nadolol can be decreased when combined with Glasdegib. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Glasdegib. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Glasdegib. |
| Naloxone | The metabolism of Glasdegib can be decreased when combined with Naloxone. |
| Naproxen | The metabolism of Glasdegib can be decreased when combined with Naproxen. |
| Nefazodone | The metabolism of Glasdegib can be decreased when combined with Nefazodone. |
| Nelfinavir | The metabolism of Glasdegib can be decreased when combined with Nelfinavir. |
| Neratinib | The serum concentration of Glasdegib can be increased when it is combined with Neratinib. |
| Netupitant | The metabolism of Glasdegib can be decreased when combined with Netupitant. |
| Nicardipine | The metabolism of Glasdegib can be decreased when combined with Nicardipine. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Glasdegib. |
| Nilotinib | The metabolism of Glasdegib can be decreased when combined with Nilotinib. |
| Nilutamide | The metabolism of Glasdegib can be decreased when combined with Nilutamide. |
| Nilvadipine | The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Glasdegib. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Glasdegib. |
| Nintedanib | The serum concentration of Nintedanib can be increased when it is combined with Glasdegib. |
| Nitrendipine | The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Glasdegib. |
| Nitrofurantoin | Glasdegib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Glasdegib. |
| Norgestimate | The serum concentration of Glasdegib can be increased when it is combined with Norgestimate. |
| Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Glasdegib. |
| Novobiocin | Novobiocin may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Octreotide | The risk or severity of QTc prolongation can be increased when Octreotide is combined with Glasdegib. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Glasdegib. |
| Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Glasdegib. |
| Olodaterol | The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Glasdegib. |
| Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Glasdegib. |
| Ombitasvir | Glasdegib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. |
| Omeprazole | Omeprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Glasdegib. |
| Orphenadrine | The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Glasdegib. |
| Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Glasdegib. |
| Oteseconazole | The serum concentration of Glasdegib can be increased when it is combined with Oteseconazole. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Glasdegib. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Glasdegib. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Glasdegib can be decreased when combined with Oxybutynin. |
| Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Glasdegib. |
| Ozanimod | Glasdegib may decrease the excretion rate of Ozanimod which could result in a higher serum level. |
| Paclitaxel | The metabolism of Paclitaxel can be decreased when combined with Glasdegib. |
| Pacritinib | The serum concentration of Glasdegib can be increased when it is combined with Pacritinib. |
| Palbociclib | Palbociclib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Glasdegib. |
| Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Glasdegib. |
| Pantoprazole | Pantoprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Glasdegib. |
| Paramethadione | The metabolism of Glasdegib can be decreased when combined with Paramethadione. |
| Paritaprevir | Paritaprevir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Pasireotide | The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Glasdegib. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Glasdegib. |
| Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Glasdegib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Glasdegib. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Glasdegib. |
| Pentobarbital | The metabolism of Glasdegib can be increased when combined with Pentobarbital. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Glasdegib. |
| Perhexiline | The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Glasdegib. |
| Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Glasdegib. |
| Phenobarbital | The metabolism of Glasdegib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Glasdegib. |
| Phenytoin | The metabolism of Phenytoin can be decreased when combined with Glasdegib. |
| Pibrentasvir | Glasdegib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Pimozide is combined with Glasdegib. |
| Pinaverium | The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Glasdegib. |
| Pioglitazone | The metabolism of Glasdegib can be decreased when combined with Pioglitazone. |
| Piroxicam | The metabolism of Glasdegib can be decreased when combined with Piroxicam. |
| Pitavastatin | Glasdegib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. |
| Pitolisant | The serum concentration of Glasdegib can be decreased when it is combined with Pitolisant. |
| Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Glasdegib. |
| Ponatinib | The metabolism of Ponatinib can be decreased when combined with Glasdegib. |
| Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Glasdegib. |
| Posaconazole | The metabolism of Glasdegib can be decreased when combined with Posaconazole. |
| Pralatrexate | Glasdegib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
| Pralsetinib | The serum concentration of Pralsetinib can be increased when it is combined with Glasdegib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Pramocaine. |
| Pravastatin | Pravastatin may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Prazosin | Glasdegib may decrease the excretion rate of Prazosin which could result in a higher serum level. |
| Prednisolone | The serum concentration of Prednisolone phosphate can be increased when it is combined with Glasdegib. |
| Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Glasdegib. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Glasdegib. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Prilocaine. |
| Primaquine | The risk or severity of QTc prolongation can be increased when Primaquine is combined with Glasdegib. |
| Primidone | The metabolism of Glasdegib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Glasdegib can be increased when combined with Probenecid. |
| Probucol | The risk or severity of QTc prolongation can be increased when Probucol is combined with Glasdegib. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Procainamide is combined with Glasdegib. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Procaine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Glasdegib. |
| Progesterone | Progesterone may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Promazine | The risk or severity of QTc prolongation can be increased when Promazine is combined with Glasdegib. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Glasdegib. |
| Propafenone | The risk or severity of QTc prolongation can be increased when Propafenone is combined with Glasdegib. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Proparacaine. |
| Propofol | The risk or severity of QTc prolongation can be increased when Propofol is combined with Glasdegib. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Propoxycaine. |
| Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Glasdegib. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Glasdegib. |
| Pyrimethamine | The metabolism of Glasdegib can be decreased when combined with Pyrimethamine. |
| Quetiapine | The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Glasdegib. |
| Quinidine | The serum concentration of Quinidine can be increased when it is combined with Glasdegib. |
| Quinine | The risk or severity of QTc prolongation can be increased when Quinine is combined with Glasdegib. |
| Rabeprazole | Rabeprazole may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Raloxifene | Glasdegib may decrease the excretion rate of Raloxifene which could result in a higher serum level. |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Glasdegib. |
| Regorafenib | The serum concentration of Regorafenib can be increased when it is combined with Glasdegib. |
| Relebactam | The excretion of Relebactam can be decreased when combined with Glasdegib. |
| Relugolix | The serum concentration of Relugolix can be increased when it is combined with Glasdegib. |
| Repaglinide | The metabolism of Glasdegib can be decreased when combined with Repaglinide. |
| Reserpine | The serum concentration of Glasdegib can be increased when it is combined with Reserpine. |
| Revefenacin | Glasdegib may decrease the excretion rate of Revefenacin which could result in a higher serum level. |
| Ribociclib | The metabolism of Glasdegib can be decreased when combined with Ribociclib. |
| Rifabutin | The metabolism of Glasdegib can be increased when combined with Rifabutin. |
| Rifampicin | The metabolism of Glasdegib can be increased when combined with Rifampicin. |
| Rifamycin | The metabolism of Glasdegib can be increased when combined with Rifamycin. |
| Rifapentine | The metabolism of Glasdegib can be increased when combined with Rifapentine. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Glasdegib. |
| Rilonacept | The metabolism of Glasdegib can be increased when combined with Rilonacept. |
| Rilpivirine | The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Glasdegib. |
| Riluzole | Glasdegib may decrease the excretion rate of Riluzole which could result in a higher serum level. |
| Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Glasdegib. |
| Riociguat | Glasdegib may decrease the excretion rate of Riociguat which could result in a higher serum level. |
| Ripretinib | Glasdegib may decrease the excretion rate of Ripretinib which could result in a higher serum level. |
| Risperidone | The risk or severity of QTc prolongation can be increased when Risperidone is combined with Glasdegib. |
| Ritonavir | The serum concentration of Glasdegib can be increased when it is combined with Ritonavir. |
| Rivaroxaban | Glasdegib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
| Rofecoxib | The metabolism of Glasdegib can be decreased when combined with Rofecoxib. |
| Rolapitant | Rolapitant may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Glasdegib. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Ropivacaine. |
| Rosiglitazone | The metabolism of Glasdegib can be decreased when combined with Rosiglitazone. |
| Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Glasdegib. |
| Rosuvastatin | Glasdegib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. |
| Roxadustat | The serum concentration of Glasdegib can be increased when it is combined with Roxadustat. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Glasdegib. |
| Rucaparib | Glasdegib may decrease the excretion rate of Rucaparib which could result in a higher serum level. |
| Rupatadine | The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Glasdegib. |
| Safinamide | Safinamide may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Glasdegib. |
| Salmeterol | The metabolism of Glasdegib can be decreased when combined with Salmeterol. |
| Sapropterin | The serum concentration of Glasdegib can be increased when it is combined with Sapropterin. |
| Saquinavir | The metabolism of Glasdegib can be decreased when combined with Saquinavir. |
| Sarecycline | The serum concentration of Glasdegib can be increased when it is combined with Sarecycline. |
| Satralizumab | The serum concentration of Glasdegib can be decreased when it is combined with Satralizumab. |
| Secobarbital | The metabolism of Glasdegib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Glasdegib can be increased when combined with Secukinumab. |
| Selegiline | The metabolism of Glasdegib can be decreased when combined with Selegiline. |
| Selexipag | The serum concentration of Selexipag can be increased when it is combined with Glasdegib. |
| Selpercatinib | The serum concentration of Glasdegib can be increased when it is combined with Selpercatinib. |
| Selumetinib | Glasdegib may decrease the excretion rate of Selumetinib which could result in a higher serum level. |
| Sevoflurane | The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Glasdegib. |
| Sildenafil | The serum concentration of Glasdegib can be increased when it is combined with Sildenafil. |
| Silodosin | The excretion of Silodosin can be decreased when combined with Glasdegib. |
| Siltuximab | The metabolism of Glasdegib can be increased when combined with Siltuximab. |
| Simeprevir | The metabolism of Glasdegib can be decreased when combined with Simeprevir. |
| Simvastatin | The serum concentration of Glasdegib can be increased when it is combined with Simvastatin. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Glasdegib. |
| Sitagliptin | The serum concentration of Sitagliptin can be increased when it is combined with Glasdegib. |
| Sofosbuvir | Glasdegib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Glasdegib. |
| Solriamfetol | The excretion of Solriamfetol can be decreased when combined with Glasdegib. |
| Somatrogon | The metabolism of Glasdegib can be increased when combined with Somatrogon. |
| Sorafenib | The metabolism of Sorafenib can be decreased when combined with Glasdegib. |
| Sotagliflozin | Sotagliflozin may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Sotalol is combined with Glasdegib. |
| Sotorasib | The serum concentration of Glasdegib can be decreased when it is combined with Sotorasib. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Glasdegib. |
| Spironolactone | The metabolism of Glasdegib can be decreased when combined with Spironolactone. |
| St. John’s Wort | The metabolism of Glasdegib can be increased when combined with St. John’s Wort. |
| Stiripentol | The metabolism of Glasdegib can be decreased when combined with Stiripentol. |
| Sulfadiazine | The metabolism of Glasdegib can be decreased when combined with Sulfadiazine. |
| Sulfamethoxazole | The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Glasdegib. |
| Sulfaphenazole | The metabolism of Glasdegib can be decreased when combined with Sulfaphenazole. |
| Sulfasalazine | Sulfasalazine may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Glasdegib. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Glasdegib. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Sultopride is combined with Glasdegib. |
| Sumatriptan | Glasdegib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
| Sunitinib | The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Glasdegib. |
| Suvorexant | The serum concentration of Glasdegib can be increased when it is combined with Suvorexant. |
| Tacrolimus | The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Glasdegib. |
| Tafamidis | The serum concentration of Glasdegib can be increased when it is combined with Tafamidis. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Glasdegib. |
| Tamoxifen | The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Glasdegib. |
| Taurocholic acid | Taurocholic acid may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Tazarotene | The metabolism of Glasdegib can be decreased when combined with Tazarotene. |
| Tazemetostat | Glasdegib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. |
| Technetium | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Glasdegib. |
| Tecovirimat | The metabolism of Glasdegib can be increased when combined with Tecovirimat. |
| Tegafur | The metabolism of Tegafur can be decreased when combined with Glasdegib. |
| Tegaserod | Glasdegib may decrease the excretion rate of Tegaserod which could result in a higher serum level. |
| Telaprevir | The metabolism of Glasdegib can be decreased when combined with Telaprevir. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Telavancin is combined with Glasdegib. |
| Telithromycin | The metabolism of Glasdegib can be decreased when combined with Telithromycin. |
| Telmisartan | Telmisartan may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Telotristat ethyl | The serum concentration of Glasdegib can be decreased when it is combined with Telotristat ethyl. |
| Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Glasdegib. |
| Teniposide | Glasdegib may decrease the excretion rate of Teniposide which could result in a higher serum level. |
| Tenofovir | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Glasdegib. |
| Tenofovir | The serum concentration of Tenofovir disoproxil can be increased when it is combined with Glasdegib. |
| Tepotinib | The serum concentration of Tepotinib can be increased when it is combined with Glasdegib. |
| Terbinafine | The metabolism of Glasdegib can be decreased when combined with Terbinafine. |
| Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Glasdegib. |
| Terfenadine | The metabolism of Glasdegib can be decreased when combined with Terfenadine. |
| Teriflunomide | The metabolism of Glasdegib can be decreased when combined with Teriflunomide. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Glasdegib. |
| Testosterone | Glasdegib may decrease the excretion rate of Testosterone which could result in a higher serum level. |
| Testosterone | Glasdegib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
| Testosterone | Glasdegib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Glasdegib. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Tetracaine. |
| Tezacaftor | The serum concentration of Tezacaftor can be increased when it is combined with Glasdegib. |
| Theophylline | The metabolism of Glasdegib can be decreased when combined with Theophylline. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Glasdegib. |
| Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Glasdegib. |
| Ticagrelor | The serum concentration of Glasdegib can be increased when it is combined with Ticagrelor. |
| Ticlopidine | The metabolism of Glasdegib can be decreased when combined with Ticlopidine. |
| Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Glasdegib. |
| Tipranavir | The metabolism of Glasdegib can be decreased when combined with Tipranavir. |
| Tivozanib | Tivozanib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Glasdegib. |
| Tocilizumab | The metabolism of Glasdegib can be increased when combined with Tocilizumab. |
| Tolbutamide | The metabolism of Glasdegib can be decreased when combined with Tolbutamide. |
| Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Glasdegib. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Glasdegib. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Glasdegib. |
| Torasemide | The metabolism of Glasdegib can be decreased when combined with Torasemide. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Toremifene is combined with Glasdegib. |
| Trametinib | The metabolism of Glasdegib can be decreased when combined with Trametinib. |
| Trastuzumab e | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Glasdegib. |
| Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Glasdegib. |
| Treprostinil | The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Glasdegib. |
| Tretinoin | The metabolism of Glasdegib can be decreased when combined with Tretinoin. |
| Triclabendazole | The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Glasdegib. |
| Trilaciclib | Glasdegib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Glasdegib. |
| Trimethadione | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Glasdegib. |
| Trimethoprim | The metabolism of Glasdegib can be decreased when combined with Trimethoprim. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Glasdegib. |
| Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Glasdegib. |
| Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Glasdegib. |
| Troglitazone | The metabolism of Glasdegib can be decreased when combined with Troglitazone. |
| Troleandomycin | The metabolism of Glasdegib can be decreased when combined with Troleandomycin. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Glasdegib. |
| Tucatinib | Tucatinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Glasdegib. |
| Umbralisib | The serum concentration of Glasdegib can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Glasdegib. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Glasdegib. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Glasdegib. |
| Vardenafil | The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Glasdegib. |
| Velpatasvir | Velpatasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Vemurafenib | The serum concentration of Glasdegib can be increased when it is combined with Vemurafenib. |
| Venetoclax | The serum concentration of Venetoclax can be increased when it is combined with Glasdegib. |
| Venlafaxine | Venlafaxine may increase the excretion rate of Glasdegib which could result in a lower serum level and potentially a reduction in efficacy. |
| Verapamil | The metabolism of Glasdegib can be decreased when combined with Verapamil. |
| Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Glasdegib. |
| Vilanterol | The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Glasdegib. |
| Viloxazine | The metabolism of Glasdegib can be decreased when combined with Viloxazine. |
| Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Glasdegib. |
| Vincristine | The excretion of Vincristine can be decreased when combined with Glasdegib. |
| Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Glasdegib. |
| Vismodegib | Vismodegib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Voclosporin | The serum concentration of Glasdegib can be increased when it is combined with Voclosporin. |
| Vorapaxar | The serum concentration of Glasdegib can be increased when it is combined with Vorapaxar. |
| Voriconazole | The serum concentration of Glasdegib can be increased when it is combined with Voriconazole. |
| Vorinostat | The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Glasdegib. |
| Vortioxetine | The metabolism of Glasdegib can be decreased when combined with Vortioxetine. |
| Voxilaprevir | Glasdegib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
| Zidovudine | Glasdegib may decrease the excretion rate of Zidovudine which could result in a higher serum level. |
| Zimelidine | The metabolism of Glasdegib can be decreased when combined with Zimelidine. |
| Ziprasidone | The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Ziprasidone. |
| Zonisamide | The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Glasdegib. |
| Zopiclone | The metabolism of Glasdegib can be decreased when combined with Zopiclone. |
| Zuclopenthixol | The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Glasdegib. |
Drug-Food Interactions
- Avoid St. John’s Wort. This herb induces CYP3A metabolism and may reduce serum levels of glasdegib.
- Take it at the same time every day.
- Take it with or without food.
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
This medication should not be used during pregnancy, as it may cause harm to the developing baby. This drug can harm a developing fetus.
Verify negative pregnancy status in females of reproductive potential within 7 days prior to initiating therapy. Advise females of reproductive potential to use effective contraception during therapy and for at least 30 days after the last dose. Advise males of the potential risk of exposure through semen and to use effective contraception, including a condom, even after a vasectomy, to avoid drug exposure to a pregnant partner or a female partner of reproductive potential during therapy and for at least 30 days after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. It is not known if this drug is present in semen. Advise males to not donate semen during therapy and for at least 30 days after the last dose. This drug may impair fertility in males of reproductive potential. Men should seek advice on effective fertility preservation before beginning therapy.
Lactation
It is not known if glasdegib passes into breast milk. Breastfeeding is not recommended while taking this medication. There are no data on the presence of this drug or its active metabolites in human milk, the effects of the drug on the breastfed child, or its effect on milk production. Because of the potential for serious adverse reactions in a breastfed child, women taking this drug should not breastfeed during therapy and for at least 30 days after the last dose.
How should this medicine be used?
Glasdegib comes as a tablet to take by mouth. It is usually given with or without food once a day for at least 6 months, or as long as your doctor recommends treatment. Take glasdegib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take glasdegib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them. If you vomit after taking glasdegib, do not take another dose. Continue your regular dosing schedule. Your doctor may need to interrupt your treatment, reduce your dose, or stop your treatment depending on your response to the medication and any side effects that you experience. Be sure to tell your doctor how you are feeling during your treatment with glasdegib.
What special precautions should I follow?
Before taking glasdegib,
- tell your doctor and pharmacist if you are allergic to glasdegib, any other medications, or any of the ingredients in glasdegib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: amiodarone (Nexterone, Pacerone), carbamazepine (Carbatrol, Equetro, Tegretol, others), chlorpromazine, cilostazol, citalopram (Celexa), clarithromycin, disopyramide (Norpace), dofetilide, donepezil (Aricept), dronedarone (Multaq), efavirenz (Sustiva, in Atripla, Symfi), escitalopram (Lexapro), flecainide (Tambocor), fluconazole (Diflucan), haloperidol (Haldol), ibutilide (Corvert), indinavir (Crixivan), itraconazole (Sporanox, Onmel), ketaconazole, methadone (Dolophine, Methadose), nefazodone, nelfinavir (Viracept), nevirapine (Viramune), ondansetron (Zofran, Zuplenz), phenobarbital, phenytoin (Dilantin, Phenytek), pimozide (Orap), pioglitazone (Actos, in Oseni, Duetact, Actoplus Met), procainamide, quinidine (in Nuedexta), rifabutin (Mycobutin), rifampin (Rifadin, Rimactane, in Rifater, Rifamate), ritonavir (Norvir, in Viekira Pak, Kaletra, Technivie), sotalol (Betapace, Sorine, Sotylize), and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with glasdegib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor what herbal products you are taking, especially St. John’s wort.
- tell your doctor if you have or have ever had prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), heart failure (condition in which the heart cannot pump enough blood to other parts of the body), or low levels of magnesium or potassium in your blood.
- tell your doctor if you are breast-feeding. You should not breast-feed during your treatment with glasdegib and for at least 30 days after your final dose.
- you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of taking glasdegib.
References
